Table 3.

Number of events, person years, crude and standardised incidence rates of all cancers other than NMSC and NMSC, in patients with RA treated with JAKis, non-TNFi bDMARDs or TNFi, by time since treatment initiation

	Events	Person years, no	Crude incidence rate per 1000 person-years	Standardised incidence rate per 1000 person-years	Fully adjusted HR*
All cancers other than NMSC
0–1 year
JAKi	20	1884	10.6	9.4	0.96 (0.58 to 1.59)
Non-TNFi	52	3815	13.6	11.4	1.11 (0.77 to 1.61)
TNFi	80	7759	10.3	10.3	1.0 (Reference)
1–2 years
JAKi	8	1358	5.9	4.9	0.67 (0.32 to 1.43)
Non-TNFi	36	3049	11.8	9.2	1.25 (0.80 to 1.96)
TNFi	51	6000	8.5	8.5	1.0 (Reference)
2 or more years
JAKi	10	754	13.2	12.2	1.36 (0.67 to 2.75)
Non-TNFi	53	4187	12.7	10.7	1.06 (0.74 to 1.53)
TNFi	82	7363	11.1	11.1	1.0 (Reference)
NMSC
0–1 year
JAKi	24	1880	12.8	11.2	1.12 (0.70 to 1.78)
Non-TNFi	40	3818	10.5	8.3	0.85 (0.57 to 1.26)
TNFi	75	7755	9.7	9.7	1.0 (Reference)
1–2 years
JAKi	20	1338	14.9	12.8	1.48 (0.87 to 2.51)
Non-TNFi	47	3041	15.5	11.8	1.43 (0.95 to 2.15)
TNFi	51	5991	8.5	8.5	1.0 (Reference)
2 or more years
JAKi	15	735	20.4	18.3	2.12 (1.15 to 3.89)
Non-TNFi	39	4168	9.4	7.3	0.86 (0.57 to 1.31)
TNFi	63	7338	8.6	8.6	1.0 (Reference)

Non-TNFI includes; rituximab; abatacept; tocilizumab. All HRs estimated from Cox models including an interaction between time since treatment initiation (0–1, 1–2, 2+ years) and treatment exposure cohort. Standardised incidence rate standardised to the age and sex distribution in the TNFi cohort.

*Fully adjusted HR: adjusted for age, sex, line of therapy, for comorbidities, SES, disease-related factors and with missing categories included for those variables with missing information.

bDMARDs, biological disease-modifying antirheumatic drugs; JAKi, Janus kinase inhibitor; NMSC, non-melanoma skin cancer; RA, rheumatoid arthritis; SES, socioeconomic status; TNFi, tumour necrosis factor inhibitor.